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A natural product-inspired synthesis of a compound collection embodying the tetrahydroindolo
[2,3-a]quinolizine scaffold was established with a ﬁve step synthesis route. An imino-Diels–Alder
reaction between Danishefsky’s diene and the iminoesters derived from tryptamines was used as a key
reaction. Reductive amination of the ketone function and amide synthesis with the carboxylic acid
derived from the ethyl ester, were used to decorate the core scaffold. Thus a compound library of 530
tetrahydroindolo[2,3-a]quinolizines was generated and submitted to European lead factory consortium
for various biological screenings.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the important obstacles in the discovery of hit and lead
structures from high throughput screening (HTS) campaigns of
compound collections is the redundancy of the core-structures or
scaffolds of the libraries.1 In many cases, library synthesis efforts
are driven by the availability of inexpensive substrates or synthesis
routes which often result in heavily compromised structural
features of molecules and yield for instance relatively ﬂat hetero-
cycles.2 Such compound collections may fail to provide interesting
starting points for drug discovery research.3 Biological relevance of
the molecular frameworks or scaffolds used in the synthesis of a
compound collection bequeaths their ability to modulate different
biological functions.4 Scaffolds of natural products for instance,
encode evolutionary selected properties for interacting with
proteins and, therefore, represent biologically prevalidated frame-
works.5 Natural product based synthesis thus employs the core
structures of natural products as scaffolds for compound collec-
tions.6 Natural product derived molecules behold the frameworks
identical with the core structure of a natural product in which
different substituents are introduced at exactly the same positionsas predetermined by nature. However, in natural-product-inspired
synthesis, closely related structural frameworks of natural prod-
ucts may be used for library synthesis.6a In this approach, not only
the relative positions and nature of substituents can be varied but
also different relative stereochemistry patterns can be generated
covering a broader chemical space of a particular structural class.
The European lead factory7 (ELF) is a consortium and a platform
where academic research groups have joined industrial partners to
build up compound collections from novel chemical space and
with structural features that pharmaceutical compound collections
have been lacking so far. In order to enrich the ELF compound
collection with natural product based structural features, we set
out to develop a synthetic access to the indole alkaloid-inspired
tetrahydroindolo[2,3-a]quinolizine scaffold and a compound col-
lection based on this framework (Fig. 1).8 Many natural products
embodying the indolo[2,3-a]quinolizine framework display a wide
range of biological activities. For instance, the antibacterial lerche-
ine (I), the antiviral natural product hirsutine (II), the cytotoxic
compound 10-hydroxyngustine (III) as well as the antiplasmodial
agent glabratine (IV, Fig. 1).9 We have previously reported the syn-
thesis and biology of anticancer centrocountins, that is, indolo-
quinolizines (V) and related phosphatase inhibitors (VI, Fig. 1).10
These ﬁndings provide further validation to employing the indo-
lo[2,3-a]quinolizine scaffold as a promising structural framework
to build compound libraries for drug discovery endeavours.
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Figure 1. Biologically active natural and synthetic molecules embodying the
tetrahydroindolo[2,3-a]quinolizine scaffold.
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library.
Table 1
Optimization of imino-Diels Alder reaction. The bold numbers are highlight the best
conditions observed in the optimization reactions
N
H NH
N
N
H
N CO2Et
O
N
H
NH
CO2Et6a, R = H
6b, R = Cl
5a, R = H
5b, R = Cl
a b
NH2
1a, R = H
1b, R = Cl
4a, R = H
4b, R = Cl
R R R R
CO2Et
Entry R Lewis acid/base Mole (%) Temp (C) Yield (%)
5 6
1 H — — 0 — 16
2 H ZnCl2 5 0 32 44
3 H Cu(OTf)2 5 0 31 36
4 H LiOMe 5 0 — —
5 H ZnCl2 5 78 38 32
6 H Yb(OTf)3 5 30 54 34
7 H Yb(OTf)3 5 78 77c 8
8 Cl Yb(OTf)3 5 78 74c 6
Conditions: aethyl glyoxylate, dry CH2Cl2, molecular sieves 4 Å, 0 C, 1 h; bDanishef-
sky’s diene, Lewis acid, CH3CN, 4–8 h; c imine formation was done at 40 C.
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2.1. Synthesis design and planning of the indoloquinolizine
library
Among different criteria set up in ELF for accepting a synthetic
proposal for a library, the most important criterion is the novelty of
the scaffold. An inspection of the molecules emanating from an
eMolecules search revealed that tetrahydro-indoloquinolizine
scaffold A or ketone B derivatives were either reported or commer-
cially available and thus were not suitable for library synthesis.
Scaffold C (Scheme 1a), though was not commercial but was part
of molecules with reported biological activities.8 Interestingly,
scaffold D embodying a carboxylic acid ester or derivatives of it
as well as scaffold E were found to be novel frameworks with no
hits found either in an eMolecules search or in other common
search engines (Sciﬁnder etc.) and were therefore chosen as the
target scaffolds for the library synthesis.
A synthetic plan for the library with three diversiﬁcation points
is presented in Scheme 1b. A hetero-Diels–Alder reaction between
Danishefsky’s diene and imines, formed from tryptamine deriva-
tives (1) and ethyl glyoxylate, would provide the tetracyclic indo-
loquinolizines (2) on acidic treatment. The ketone function in
compound 2 can be elaborated further by reductive amination
with various amines. Ester saponiﬁcation would lead to acid
derivatives 3 which can provide a handle for further combinatorial
synthetic steps to build up a compound library (Scheme 1b).
2.2. Synthesis optimization of the tetrahydroindolo[2,3-
a]quinolizine scaffold
As depicted in the synthesis plan (Scheme 1b), tryptamine 1a
was treated with freshly distilled ethyl glyoxylate to obtain imine
4a11 which was used directly without puriﬁcation for imino-
Diels–Alder (IDA) reactions. In the absence of Lewis acid no product
formationwas observed (Table 1, entry 1). Mediation by Lewis acids
such as ZnCl2, and Cu(OTf)2 at 0 C afforded Pictet–Spenglerproducts 6 as the major product (Table 1, entries 2 & 3). The IDA
reaction was also tested with a Lewis base (LiOMe) at 0 C based
on a recent report by Mukaiyama and co-workers,12 but did not
yield any desired product (Table 1, entry 4). The reactionwith ZnCl2
at78 C encouragingly yielded a slight excess of the desired prod-
uct 5a (Table 1, entry 5). However, the isolation of 5a from the crude
reaction mixture was highly tedious and contaminations from
different impurities remained with cycloadduct 5a after column
chromatographic puriﬁcation. Interestingly, IDA reaction catalyzed
by Yb(OTf)3 at 30 C was not only high yielding for 5a but also the
puriﬁcation of 5a was simple in the absence of side reactions
(Table 1, entry 6). Further reaction condition optimization led to
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Scheme 2. Reductive amination and amide synthesis. Reagents and conditions: (a)
piperidine, NaBH3(CN), AcOH, dry THF, molecular sieves 4 Å, rt, 6 h; (b) piperidine,
NaBH(OEh)3, EhOH, THF/CH2Cl2, molecular sieves 4 Å, rt, 6 h. Eh = 2-ethylhexanoyl;
(c) concd HCl, reﬂux, 10 h; (d) diethylamine, EDC, HOBt, DIPEA, DMF, 0 C to rt, 63%;
(e) n-propylamine, EDC, HOBt, DIPEA, DMF, 0 C to rt, 67%.
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from tryptamine 1a and ethyl glyoxylate at40 C was followed by
treatment with Danishefsky’s diene in the presence of catalytic
Yb(OTf)3 (5 mol %) at 78 C in a one pot fashion affording the
vinylogous amide 5a in 77% yield on a 1.8 mmol scale (Table 1,
entry 7). Reaction sequence was further scaled up to 18.1 mmol
scale using similar reaction conditions which afforded the product
5a in 67% yield. Under the optimized reaction conditions and
employing 5-chlorotryptamine 1b derived imine 4b (4.2 mmol),
the expected vinylogous amide 5b was obtained in 74% yield
(Table 1, entry 8).
Our attempts to get the tetracyclic indoloquinolizines (2) from
tryptamine 1a in one pot as shown in the Scheme 1, however,
remained unsuccessful. Hence the cyclization of the vinylogous
amide 5a to provide 2a was tested with different acids as a sepa-
rate step. Treatment of compound 5a with triﬂuoroacetic acid, tri-
ﬂic acid and sulfuric acid did not yield the desired product 2a
(Table 2, entries 1–4). Treatment of compound 5a with hydrochlo-
ric acid in ethanol did not provide the expected compound (Table 1,
entry 5), but resulted in the formation of a 1:1 mixture of the
diethyl ketal and enol ethyl ether derivative of compound 2a. Inter-
estingly, when the amide 5a (0.5 mmol scale) was treated with a
4 M solution of hydrochloric acid in dioxane (10 equiv) the
expected tetracyclic compound 2a was obtained in 69% yield with
4:1 diastereomeric ratio (Table 2, entry 6). No change in the diaste-
reoselectivity was observed when the same reaction was per-
formed at higher scale (4.1 mmol).
However, the cyclization reaction of the amide 5bwith 4 M solu-
tion of HCl in dioxane (10 equiv) led to little conversion (<10%) at
room temperature (Table 2, entry 7). Under reﬂux condition, the
cyclization did proceed but afforded 2b in a poor yield and with
1:1 diastereoselectivity (Table 2, entry 8). Interestingly, treatment
of the amide 5b (1.3 mmol scale)with continuous and constant ﬂow
of HCl (g) in dioxane resulted in the formation of the tetracycle 2b in
good yield andwith a 5:1 diastereomeric ratio (Table 2, entry 9). The
relative stereochemistry of the tetracyclic compound 2bwas unam-
biguously conﬁrmed by single crystal X-ray analysis.13Table 2
Cyclization of vinylogous amide 5. The bold numbers are highlight the best conditions ob
5a: R = H
5b: R = Cl
2a: R = H
2b: R = Cl
acid
N
H
N
O
R
CO2Et
N
H
N
O
R
CO2Et
H
Entry R Acida Solvent
1 H CF3CO2Hb CH2Cl2
2 H CF3CO2H CH2Cl2
3 H CF3SO3H CH2Cl2
4 H H2SO4 CH3CN
5 H HCl (g) EtOH
6 H HCl Dioxane
7 Cl HCl Dioxane
8 Cl HCl Dioxane
9 Cl HCl (g) Dioxane
a Reactions were performed at 0 C to rt unless otherwise speciﬁed.
b Reaction was performed at 78 C.
c 1:1 mixture of diethyl ketal and enol ethyl ether derivative of compound 2a was ob
d The reaction was performed at reﬂux temperature for 4 h.Reductive amination of the tetracyclic compound 2a by a stan-
dard protocol using sodium cyanoborohydride in acetic acid affor-
ded the amine derivative 7a in very good yield with 4:1
diastereomeric ratio (Scheme 2, entry 1). While the separation of
the two isomers was very difﬁcult, we resorted to a highly stereo-
selective reductive amination. To this end, we observed that the
use of bulkier trialkoxyborohydride can provide the desired adduct
7 in a very good yield and in a highly stereoselective manner.13 As
expected, the reductive amination of 2a with the piperidine, using
sodium tri(2-ethylhexanoyloxy) borohydride as reducing agent
afforded the amine compound 7a in an excellent yield and diaste-
reoselectivity (>30:1) (Scheme 2, entry 2). The relative stereo-
chemistry of the product 7a was established by NOESY analysis
(see the Supporting information). Similarly, the stereoselective
reductive amination of 2a with N-methylpiperazine employingserved in the optimization reactions
2b 
Product Yield (%) dr
2a 0 —
2a 0 —
2a 0 —
2a 0 —
2a 0c —
2a 69 4:1
2b <10 —
2b 28d 1:1
2b 62 5:1
served.
Table 3
Representative examples for the reductive amination step
7 R1 R2 Yield (%) 7 R1 R2 Yield (%)
7a H
HN
81 7i Cl
HN
78
7b H
HN
O
62 7j Cl
HN
O
59
7c H
HN
99 7k Cl HN 68
7d H HN 57 7l Cl HN 48
7e H HN 77 7m Cl HN 72
7f H HN 16 7n Cl
HN
42
7g H
HN
N 66 7o Cl
HN
70
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excellent yield and diastereoselectivity (>30:1) (Scheme 2, entry
3). The reductive amination of 2a with primary amines for
instance, n-propylamine was also high yielding as well as highly
stereoselective (7c, Scheme 2, entry 4). Likewise, the chloro deriv-
ative 2b upon treatment with piperidine under similar reaction
conditions provided the desired product 7d in 92% yield with a
very good diastereoselectivity (>20:1) (Scheme 2, entry 5).
In order to have a carboxylic acid function, which can be
explored in a combinatorial step to build a compound collection,
we explored the hydrolysis of the ethyl ester avoiding any possible
epimerization. Thus, compound 7b was hydrolyzed to the corre-
sponding carboxylic acid 3 under acidic conditions (Scheme 2).
The crude carboxylic acid (3) was used in the amide coupling with
diethyl- and n-propylamine using EDC, HOBt and DIPEA affording
the amide derivative 8a and 8b respectively in good yields (63–
67%) over two steps.
2.3. Generation of a tetrahydroindolo[2,3-a]quinolizine library
Synthesis optimization of the core-scaffold followed the design
of a library containing 3 points of diversity, as shown in Scheme 3.
A matrix of 2  12  24 using tryptamine derivatives, secondary
amines and amines, respectively, was selected to ensure that at
least 80% of the ﬁnal compounds have ‘lead-like’ properties. The
physicochemical constraints, commercial availability, cost and
reactivity considerations prompted us to select monoatomic sub-
stituents (H, Cl) at position 6 of the starting tryptamine and small
or polar secondary amines for the reductive amination step. This
allowed for a wider structural diversity to be installed via amines
at the ﬁnal amide coupling step (Table 3).
The key one-pot imination/imino Diels–Alder reaction pro-
ceeded well at higher scales too. The use of HPLC quality DCM
proved a better choice over the distilled solvent. Acidic cyclization
of the vinylogous amides 5was afforded byusing 4 MHCl in dioxane
instead of HCl (g). Although this required a longer reaction time
(144 vs 36 h), this procedure maintained the adequate conversion
to the products (68–74%). Importantly, the diastereomeric ratio in
the formation of the IDA products was not affected (dr = 4:1,
Scheme 3).N
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Scheme 3. Production of the tetrahydroindolo[2,3-a]quinolizine library. Reagents
and conditions: (a) ethyl glyoxylate, dry CH2Cl2, molecular sieves 4 Å, 40 C, N2
atmosphere, 1 h; (b) Danishefsky’s diene, Yb(OTf)3, CH3CN, 78 C, N2 atmosphere,
overnight; (c) HCl 4 M in dioxane, 0 C to rt, 7 days or HCl(g), dioxane, 0 C to rt,
36 h; (d) amine, NaBH(OEh)3, EhOH, THF/CH2Cl2, molecular sieves 4 Å, N2 atmo-
sphere, rt, 6–24 h; (e) concd HCl, reﬂux, 10–36 h (f) amine, HOBt, EDCHCl, DIPEA,
DMF, 50 C, N2 atmosphere, 18 h.The chemistry optimized in the synthetic validation of the scaf-
fold tetrahydroindolo[2,3-a]quinolizine (Tables 1 and 2 and
Scheme 2) was generally reproducible in the library production
phase across various substrates used and yields were overall com-
parable to the ones reported at smaller scale, as summarized in
Table 3 for a subset of amines used in the reductive amination step.
The validated procedure for the last diversiﬁcation step, using
HATU as amide coupling agent was found not to be general enough
for the parallel synthesis using 15 mL reaction tubes in a 24 posi-
tion Mettler Toledo Miniblock. A different protocol using EDC
and HOBt in DIPEA proved to be efﬁcient. Initially, an EDC: HOBt
ratio of 1.5:2.0 equiv was employed, but the detection of signiﬁ-
cant amounts of by-products in the uHPLC analysis with the mass
of corresponding carboxylic acid/HOBt intermediate led us to a
ﬁnal stoichiometry of 1.8:1.5 equiv With this scaffold-optimized
amidation protocol, 530 compounds of sufﬁcient quantity
(>5 lmol) and purity (LC–MS >85%), were synthesized and isolated
(92% success rate) after HPLC/MS-based analysis and puriﬁcation.
3. Conclusion
A synthetic route to structurally complex tetrahydroindolo[2,3-
a]quinolizines was established using an imino-Diels–Alder reac-
tion as the key step and leading to a compound library of more
than 500 members. Synthetic validation of the scaffold was per-
formed in multigram scale reactions and successfully transferred
in the production phase of the library. In the latter case, reductive
amination of cyclic ketones and amide synthesis were used as syn-
thetic steps to build up a compound collection for the European
lead factory consortium. The library is currently being exposed to
various HTS campaigns and the results will be made public in
due course of time.
4. Experimental
4.1. General methods
Unless otherwise noted, all reagents and solventswere purchased
commercial suppliers and were used without further puriﬁcation
without further puriﬁcation. Thin layer chromatography (TLC) was
performed on Merck silica gel 60F254 aluminum sheet. For ﬂash
chromatography Baker silica gel (40–70 lm) was used. 1H and 13C
NMR spectroscopic data were recorded on a Varian Mercury VX
400 or Varian 500-inova500 spectrometer at RT. 1H and 13C NMR
spectra were calibrated to the solvent signals of CDCl3 (=7.26 and
77.00 ppm) and the coupling constants are displayed in Hz. Fast
atom bombardment (FAB)-MS measurements were taken on
2618 M. G. Sankar et al. / Bioorg. Med. Chem. 23 (2015) 2614–2620Finnigan MAT MS70 spectrometer and electrospray ionization (ESI)-
MS were measured by using an Agilent 1100 series binary pump
together with a reversed-phase HPLC column (Macherey-Nagel).
4.2. Ethyl 1-(2-(1H-indol-3-yl)ethyl)-4-oxo-1,2,3,4-tetrahydro-
pyridine-2-carboxylate (5a)
Activated molecular sieves 4 Å (500 mg/1.00 mmol substrate)
were taken in a dry 250 mL round bottom (RB) ﬂask, and to this
dry CH2Cl2 (10 mL) was added followed by tryptamine
(1.872 mmol) under argon atmosphere. The solution was cooled
to 40 C and stirred for 10 min. Then, freshly distilled ethyl gly-
oxylate (2.0 mmol, 1.05 equiv) was added dropwise. The reaction
mixture was continued to stir at the same temperature for 2 h.
TLC analysis showed complete conversion of tryptamine. The reac-
tion mixture was again cooled down to78 C and after stirring for
another 10 minutes at 78 C, Danishefsky’s diene (2.0 mmol,
1.05 equiv) was added dropwise over 10 minutes followed by a
dropwise addition of the solution of ytterbium triﬂate (0.094 mmol,
0.05 equiv) in acetonitrile (1 mL). The reaction mixture was contin-
ued to stir at 78 C for 3–6 h. After completion of the reaction, it
was warmed to room temperature and ﬁltered through sintered
funnel and washed with CH2Cl2 (50 mL). The combined ﬁltrate
was washed with saturated sodium bicarbonate solution (10 mL),
water (10 mL), dried over anhydrous sodium sulfate and concen-
trated under reduced pressure to give a crude compound. The crude
compound was puriﬁed by ﬂash column chromatography over sil-
ica gel (0.04–0.06 mm particle size, 60 times of the weight of the
crude compound) using 2–5% methanol in dichloromethane
(DCM) as a gradient eluent to afford the pure IDA adduct 5a in
77% yield. 1H NMR (400 MHz, CDCl3) d 9.11 (s, 1H), 7.54 (d,
J = 7.8 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.11
(t, J = 7.6 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H),
4.89 (d, J = 7.5 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.93 (dd, J = 7.4,
2.8 Hz, 1H), 3.71–3.61 (m, 1H), 3.58–3.46 (m, 1H), 3.04 (t,
J = 6.6 Hz, 2H), 2.71 (dd, J = 16.7, 2.8 Hz, 1H), 2.64 (dd, J = 16.7,
7.5 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d
189.3, 170.3, 154.3, 136.8, 127.0, 123.1, 122.3, 119.6, 118.3, 112.0,
111.4, 98.4, 62.3, 59.6, 56.1, 37.9, 26.1, 14.3. HRMS [ESI]: calculated
for C18H21N2O3 [M+H+]: 313.15467. Found: 313.15463.
4.3. Ethyl 1-(2-(5-chloro-1H-indol-3-yl)ethyl)-4-oxo-1,2,3,
4-tetrahydropyridine-2-carboxylate (5b)
Following the similar procedure above (Section 4.2), 5-chlorot-
ryptamine (4.37 mmol) was converted to an imine at 40 C fol-
lowed by the IDA reaction of the imine with Danishefsky’s diene
(4.58 mmol) at 78 C that gave compound 5b in 74% yield after
ﬂash column chromatography puriﬁcation using 2–5% methanol
in dichloromethane as an eluent. 1H NMR (400 MHz, CDCl3) d
9.11 (s, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.12
(dd, J = 8.6, 2.0 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 6.90 (d, J = 7.6 Hz,
1H), 4.87 (d, J = 7.6 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.94 (dd,
J = 7.1, 2.6 Hz, 1H), 3.65 (dt, J = 13.7, 8.6 Hz, 1H), 3.51 (dt, J = 20.2,
6.4 Hz, 1H), 2.99 (t, J = 6.6 Hz, 2H), 2.75–2.69 (m, 1H), 2.65 (dd,
J = 16.7, 7.5 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz,
CDCl3) d 189.2, 170.2, 154.2, 135.1, 128.0, 125.4, 124.5, 122.7,
117.8, 113.0, 111.2, 98.6, 62.4, 59.6, 55.9, 37.9, 25.9, 14.3. HRMS
[ESI]: calculated for C18H20ClN2O3 [M+H+]: 347.11570. Found:
347.11572.
4.4. Ethyl 2-oxo-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]
quinolizine-4-carboxylate (2a)
The IDA adduct 5a (4.16 mmol) was taken in a dry 50 mL RB
ﬂask and to this dry dioxane (2 mL) was added. It was stirred for10 minutes at room temperature to make a clear solution. Then
it was cooled to 0 C and stirred for 15 min. To this reaction mix-
ture 21 mL of HCl in dioxane (4 N, 83.24 mmol) was added drop-
wise at 0 C and the reaction mixture was stirred at the same
temperature for 1 h. Then it was allowed to stir at rt for 24 h.
The solvent was removed under reduced pressure and was diluted
with DCM (50 mL). This solution was washed with saturated
sodium bicarbonate solution (20 mL) followed by water (20 mL)
and dried over anhydrous sodium sulfate. It was concentrated
under reduced pressure to give crude product as mixture of iso-
mers (4:1 diastereomeric ratio). The crude compound was puri-
ﬁed by ﬂash column chromatography over silica gel (0.04–
0.06 mm particle size, 100 times of the weight of crude compound)
using 1–4% ethyl acetate in dichloromethane as an eluent to afford
pure tetracyclic compound 2a in 69% yield. 1H NMR (400 MHz,
CDCl3) d 8.03 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.34 (d, J = 7.9 Hz,
1H), 7.17 (t, J = 7.4 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 4.50 (d,
J = 10.1 Hz, 1H), 4.26–4.14 (m, 2H), 4.11 (dd, J = 6.7, 1.9 Hz, 1H),
3.31 (dd, J = 12.2, 4.5 Hz, 1H), 3.14–2.96 (m, 2H), 2.95–2.77 (m,
3H), 2.66 (d, J = 15.0 Hz, 1H), 2.56 (dd, J = 14.4, 11.1 Hz, 1H), 1.28
(t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 205.48, 170.80,
136.53, 133.70, 127.11, 122.09, 119.85, 118.41, 111.27, 108.30,
63.87, 61.39, 52.46, 50.49, 45.57, 43.16, 22.21, 14.65. HRMS [ESI]:
calculated for C18H21N2O3 [M+H+]: 313.15467. Found: 313.15469.
4.5. Ethyl 9-chloro-2-oxo-1,2,3,4,6,7,12,12b-octahydroindolo-
[2,3-a]quinolizine-4-carboxylate (2b)
To a solution of IDA adduct 5b (1.3 mmol) in dry dioxane
(10 mL), dry HCl (g) (generated by the reaction between 5 g of NaCl
and 10 mL of Conc. H2SO4) was purged in to the solution for 60 min
at 0 C and was stirred at the same temperature for 1 h. Then it was
allowed to stir at rt for 36 h until completion. The solvent was
removed under reduced pressure and was diluted with DCM
(30 mL). This solution was washed with saturated sodium bicar-
bonate solution (10 mL) followed by water (10 mL) and dried over
sodium sulfate and concentrated under reduced pressure to give
crude product (5:1 diastereomeric ratio). The crude compound
was puriﬁed by column chromatography over ﬂash silica gel
(0.04–0.06 mm particle size, 100 times the weight of the crude
compound) using 0.0–0.6% methanol in dichloromethane to give
the title compound 2b in 62% yield. 1H NMR (400 MHz, CD2Cl2) d
8.28 (s, 1H), 7.47 (s, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.10 (dd, J = 8.7,
1.5 Hz, 1H), 4.45 (d, J = 11.2 Hz, 1H), 4.27–4.15 (m, 2H), 4.11 (d,
J = 6.6 Hz, 1H), 3.30 (dd, J = 11.3, 4.0 Hz, 1H), 3.05 (td, J = 11.1,
3.8 Hz, 1H), 3.00–2.79 (m, 3H), 2.76 (dd, J = 14.8, 1.6 Hz, 1H),
2.65–2.50 (m, 2H), 1.29 (tt, J = 7.1, 1.3 Hz, 3H); 13C NMR
(101 MHz, CD2Cl2) d 205.4, 170.9, 135.9, 134.9, 128.3, 125.1,
121.8, 117.8, 112.2, 108.1, 63.9, 61.3, 52.2, 50.3, 45.5, 43.1, 22.2,
14.4. HRMS [ESI]: calculated for C18H20ClN2O3 [M+H+]:
347.11570. Found: 347.11568.
4.6. Ethyl 2-(piperidin-1-yl)-1,2,3,4,6,7,12,12b-octahydro-
indolo[2,3-a]quinolizine-4-carboxylate (7a)
The tetracyclic keto compound 2a (0.42 mmol) was dissolved in
dry THF (3 mL), and an equivalent weight of activated, cooled 4 Å
molecular sieves was added followed by addition of 2-ethylhexa-
noic acid (0.42 mmol) and piperidine (0.62 mmol). The ﬂask was
ﬂushed with argon and the solution was stirred at room tempera-
ture for 1 h. NaBH(OEh)3 (0.83 mmol) dissolved in DCM (3 mL) was
then added under argon atmosphere and the mixture was stirred
for further 4 h at room temperature. Saturated aqueous NaHCO3
solution (10 mL) was added to the reaction mixture followed by
DCM (20 mL). The extracted organic layer was collected and
washed with water (10 mL), dried over anhydrous sodium sulfate
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puriﬁed by ﬂash column chromatography using 4–8% methanol
in dichloromethane as an eluent to afford pure compound 7a
(150 mg, 94% yield). 1H NMR (400 MHz, CDCl3) d 8.22 (s, 1H),
7.46 (d, J = 7.5 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.17–7.12 (m, 1H),
7.11–7.06 (m, 1H), 4.72 (s, 1H), 4.32–4.17 (m, 2H), 3.53 (dd,
J = 11.3, 2.9 Hz, 1H), 3.36 (dd, J = 14.1, 5.6 Hz, 1H), 3.25–3.16 (m,
1H), 3.04–2.91 (m, 1H), 2.68–2.61 (m, 2H), 2.55 (dd, J = 16.0,
4.5 Hz, 1H), 2.50–2.38 (m, 3H), 2.35–2.19 (m, 2H), 1.97–1.91 (m,
1H), 1.72 (dd, J = 23.2, 11.7 Hz, 1H), 1.67–1.53 (m, 4H), 1.48–1.41
(m, 2H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d
183.0, 173.5, 136.2, 132.8, 127.7, 121.7, 119.6, 118.1, 111.5,
108.3, 61.2, 57.9, 57.6, 55.2, 49.8, 48.6, 30.6, 29.2, 25.8, 24.5,
17.1, 14.5. HRMS [ESI]: calculated for C23H32N3O2 [M+H+]:
382.24890. Found: 382.24888.
4.7. Ethyl 2-(4-methylpiperazin-1-yl)-1,2,3,4,6,7,12,12b-
octa-hydroindolo[2,3-a]quinolizine-4-carboxylate (7b)
Following the similar procedure (Section 4.6), the tetracyclic
keto compound 2a (0.32 mmol) was treated with N-methyl piper-
azine (0.48 mmol) in the presence of ethylhexanoic acid
(0.32 mmol) and NaBH(OEh)3 (0.64 mmol) to get the crude product
that was puriﬁed by ﬂash column chromatography using 4–8%
methanol in dichloromethane as an eluent to afford pure com-
pound 7b (122 mg, 96% yield). 1H NMR (400 MHz, CDCl3) d 8.17
(s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.16 (t,
J = 7.5 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 4.72 (s, 1H), 4.31–4.18 (m,
2H), 3.54 (dd, J = 10.7, 2.7 Hz, 1H), 3.34 (dd, J = 13.9, 5.6 Hz, 1H),
3.27–3.17 (m, 1H), 3.04–2.92 (m, 1H), 2.89–2.74 (m, 1H), 2.73–
2.64 (m, 2H), 2.59–2.38 (m, 6H), 2.28 (s, 3H), 2.25–2.19 (m, 2H),
1.95 (d, J = 12.5 Hz, 1H), 1.75 (q, J = 11.7 Hz, 1H), 1.29 (t,
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 181.2, 173.5, 136.0,
133.0, 127.7, 121.8, 119.8, 118.3, 111.3, 108.7, 61.1, 58.1, 56.7,
55.2, 54.6, 48.7, 48.6, 46.1, 46.0, 31.0, 29.9, 17.4, 14.5. HRMS
[ESI]: calculated for C23H33N4O2 [M+H+]: 397.25980. Found:
397.25982.
4.8. Ethyl 2-(propylamino)-1,2,3,4,6,7,12,12b-octahydroindolo-
[2,3-a]quinolizine-4-carboxylate (7c)
Following the similar procedure (Section 4.6), the tetracyclic
keto compound 2a (0.16 mmol) was treated with n-propylamine
(0.24 mmol) in the presence of ethylhexanoic acid (0.16 mmol)
and NaBH(OEh)3 (0.32 mmol) to get the crude product that was
puriﬁed by ﬂash column chromatography using 5–10% methanol
in dichloromethane as an eluent to afford pure compound 7c
(40 mg, 69% yield). 1H NMR (400 MHz, CDCl3) d 8.07 (s, 1H), 7.47
(d, J = 7.6 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.17–7.12 (m, 1H),
7.12–7.07 (m, 1H), 4.70 (s, 1H), 4.30–4.15 (m, 2H), 3.58 (dd,
J = 8.7, 4.0 Hz, 1H), 3.35–3.21 (m, 2H), 3.02–2.89 (m, 1H), 2.72–
2.64 (m, 1H), 2.64–2.54 (m, 2H), 2.53–2.46 (m, 1H), 2.23–2.06
(m, 2H), 2.02–1.96 (m, 2H), 1.74 (dt, J = 12.3, 8.6 Hz, 1H), 1.54–
1.42 (m, 2H), 1.30 (t, J = 7.1 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H); 13C
NMR (101 MHz, CDCl3) d 173.8, 136.1, 134.0, 127.8, 121.7, 119.7,
118.2, 111.1, 108.5, 60.9, 58.4, 52.5, 50.7, 49.2, 48.8, 35.4, 34.9,
23.6, 18.7, 14.5, 12.0. HRMS [ESI]: calculated for C21H30N3O2
[M+H+]: 356.23325. Found: 356.23321.
4.9. Ethyl 9-chloro-2-(piperidin-1-yl)-1,2,3,4,6,7,12,12b-octa-
hydroindolo[2,3-a]quinolizine-4-carboxylate (7d)
Following the similar procedure Section 4.6, the tetracyclic keto
compound2b (0.09 mmol)was treatedwith piperidine (0.13 mmol)
in the presence of ethylhexanoic acid (0.09 mmol) and NaBH(OEh)3
(0.18 mmol) to get the crude. The crude compound was puriﬁed byﬂash column chromatography using 4–8% methanol in dichloro-
methane as eluent to afford pure compound 7d (122 mg, 92% yield).
1H NMR (400 MHz, CDCl3) d 9.13 (s, 1H), 7.40 (d, J = 1.5 Hz, 1H), 7.29
(d, J = 8.6 Hz, 1H), 7.08 (dd, J = 8.6, 2.0 Hz, 1H), 4.69 (s, 1H), 4.32–
4.17 (m, 2H), 3.49 (dd, J = 11.2, 2.8 Hz, 1H), 3.34 (dd, J = 14.3,
5.9 Hz, 1H), 3.25–3.14 (m, 1H), 2.98–2.87 (m, 1H), 2.82–2.71 (m,
2H), 2.68–2.58 (m, 2H), 2.57–2.48 (m, 3H), 2.23 (td, J = 13.1,
4.8 Hz, 1H), 1.93 (dd, J = 11.8, 2.6 Hz, 1H), 1.82–1.62 (m, 5H),
1.53–1.43 (m, 2H), 1.30 (td, J = 7.1, 0.9 Hz, 3H); 13C NMR
(101 MHz, CDCl3) d 183.2, 173.0, 134.7, 134.0, 128.7, 125.3, 122.0,
117.7, 112.7, 108.1, 61.4, 58.2, 57.8, 55.1, 49.7, 49.5, 48.4, 30.3,
28.7, 25.2, 24.1, 16.9, 14.5. HRMS [ESI]: calculated for C23H31ClN3O2
[M+H+]: 416.20993. Found: 416.20991.
4.10. N,N-Diethyl-2-(4-methylpiperazin-1-yl)-1,2,3,4,6,7,12,-
12b-octahydroindolo[2,3-a]quinolizine-4-carboxamide (8a)
A mixture of reductive amination product 7b (0.09 mmol) and
conc. HCl (2 mL) was reﬂuxed overnight. TLC and LCMS analysis
were used to monitor the reaction. After completion, the solvent
was removed under vacuum to give the crude product 3 (quantita-
tive) and was used directly for the next step without puriﬁcation.
The crude acid 3was dissolved in dry DMF (2 mL) and treated with
DIPEA (0.45 mmol) followed by HOBt (0.226 mmol), diethylamine
(0.1 mmol) and EDC (0.2 mmol) at 0 C and the reaction mixture
was allowed to stir at room temperature for 10 h. TLC was used
to monitor the completion of the reaction. After completion, the
solvent was removed in vacuo to give crude. The crude mixture
was puriﬁed by ﬂash column chromatography using 5–10% meth-
anol in DCM as an eluent to afford pure compound 8a (0.06 mmol)
in 63% yield. 1H NMR (400 MHz, CDCl3) d 8.20 (s, 1H), 7.45 (d,
J = 7.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.3 Hz, 1H), 7.07
(t, J = 7.4 Hz, 1H), 3.55–3.31 (m, 6H), 3.21–3.05 (m, 1H), 2.98–
2.85 (m, 1H), 2.82–2.52 (m, 11H), 2.41–2.49 (m, 1H), 2.36 (s, 3H),
2.32–3.24 (m, 2H), 1.99–1.91 (m, 1H), 1.22–1.19 (m, 3H), 1.16 (t,
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 171.0, 136.2, 134.5,
127.4, 121.7, 119.6, 118.3, 111.2, 108.6, 13C NMR (101 MHz, cdcl3)
d 13C NMR (101 MHz, CDCl3) d 171.0, 136.2, 134.5, 127.4, 121.7,
119.6, 118.3, 111.2, 108.6, 61.4, 55.0, 48.8, 48.7, 48.4, 48.3, 45.5,
44.2, 44.0, 42.1, 40.8, 30.9, 30.5, 22.1, 13.2, 13.1. HRMS [ESI]: calcu-
lated for C25H38N5O [M+H+]: 424.30709. Found: 424.30711.
4.11. 2-(4-Methylpiperazin-1-yl)-N-propyl-1,2,3,4,6,7,12,12b-
octahydroindolo[2,3-a]quinolizine-4-carboxamide (8b)
A mixture of reductive amination product 7b (0.09 mmol) and
conc. HCl (2 mL) was reﬂuxed overnight. TLC and LCMS analysis
were used to monitor the reaction. After completion, the solvent
was removed under vacuum to give the crude product 3 (quantita-
tive) and was used directly for the next step without puriﬁcation.
The crude acid 3was dissolved in dry DMF (2 mL) was treated with
DIPEA (0.45 mmol) followed by HOBt (0.226 mmol), n-propylamine
(0.135 mmol) and EDC (0.2 mmol) at 0 C and was allowed to stir at
room temperature for 10 h. TLC was used to monitor the comple-
tion of reaction. After completion, the solvent was removed in
vacuo to give crude product that was puriﬁed by ﬂash column chro-
matography using 5–10% methanol in dichloromethane as an elu-
ent to afford pure compound 8b (0.06 mmol) in 67% yield. 1H
NMR (400 MHz, CDCl3) d 8.41 (s, 1H), 7.39 (d, J = 7.3 Hz, 1H), 7.28
(d, J = 7.8 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 7.02 (t, J = 7.0 Hz, 1H),
6.59 (t, J = 5.6 Hz, 1H), 3.36 (d, J = 11.2 Hz, 1H), 3.33–3.21 (m, 2H),
3.15–2.98 (m, 3H), 2.90 (d, J = 11.8 Hz, 1H), 2.83–2.74 (m, 1H),
2.73–2.62 (s, 4H), 2.60–2.49 (m, 3H), 2.48–2.32 (m, 3H), 2.30 (s,
3H), 2.22–2.15 (m, 1H), 1.55–1.39 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) d 173.6, 136.2, 134.4, 127.3, 121.9,
119.8, 118.3, 111.3, 108.3, 67.8, 60.6, 58.5, 55.0, 51.2, 48.7, 45.6,
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C24H36N5O [M+H+]: 410.29144. Found: 410.29140.
4.12. General procedure for EDC/HOBt-based amide coupling
reactions
Reactions were performed in parallel in 15 mL reaction tubes in
a 24 position Mettler-Toledo Miniblock equipped with a heat
transfer block and inert gas manifold. Each reaction tube was
loaded with a solution of the appropriate carboxylic acid 3a-z
(40.0 mg, 1 equiv, 0.5 mL as a 0.18 M stock solution in dry DMF),
and DIPEA (9 equiv, 1.62 M) and stirred for 5 min at room temper-
ature under nitrogen. HOBt (1.5 equiv, 0.1 mL as a 1.3 M stock solu-
tion in dry DMF) was added then and after 2 min the amine
(3 equiv of primary amine or 5 equiv if secondary amine, as a
DMF solution) and neat EDCHCl (2 equiv). The Mettler Block was
closed and the reactions were stirred at 50 C for 18 h. Volatiles
were evaporated in a centrifugal evaporator and the residue was
redissolved in MeOH (1.0 mL). Crude methanolic solutions were
transferred to 96 position ﬁltration plates and centrifuged into
96 deep-well plates for uHPLC/MS analysis and HPLC puriﬁcation.
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